Hyperion raises $60M to battle urea cycle disorders
Hyperion Therapeutics, developer of treatments for urea cycle disorders and illnesses, has brought in $60 million in a third round of financing from Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates and Sofinnova Ventures.
Based in South San Francisco, the company recently completed phase-two clinical trials for its lead drug candidate and says the new capital will be used to push it through phase three. This therapy is targeted at patients who are… Continue Reading
Life sciences briefing: Thursday, Oct. 4, 2007
Featured companies: 23andMe, APT Pharmaceuticals, Hyperion Therapeutics, Isis Biopolymer, Virogenomics
UPDATED at 10:30am PT.
APT Pharma raises $22M for transplant and heart drugs — Burlingame, Calif.’s APT Pharmaceuticals, a specialty pharma currently focused on a drug to fight organ-transplant rejection, raised $22 million in an extension of its first funding round. Investors included Versant Ventures, Great Point Partners, Vivo Ventures and Charter Life Sciences.
APT, which acquires its drug candidates instead of developing them itself, has raised a total of… Continue Reading
Life sciences briefing: Wednesday, Sept. 5, 2007
Featured companies: Atritech, Avalon Partners, Ensemble Discovery, Hyperion Therapeutics, LifeBond, ReShape Medical, SafeStitch, Trophos, UltraShape
Hyperion Therapeutics raises $40M against GI and kidney disease — Hyperion Therapeutics, a South San Francisco, Calif., specialty pharmaceutical company, raised $40 million in a second funding round. Investors included Sofinnova Ventures, Highland Capital Partners, New Enterprise Associates and WRF Capital.
Hyperion, which buys the rights to test and market drug candidates from other companies, said the proceeds will allow it to complete… Continue Reading